Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309%

Related Keywords

New York ,United States ,Ottawa ,Ontario ,Canada ,Canadian ,Joe Oconnor ,Barbara Shecter ,Goldy Hyder ,Darren Opland ,Mark Jacobson ,Herriot Tabuteau ,Gabriel Friedman ,World Trade Center ,Postmedia Network Inc ,Corporate Communications ,Nasdaq ,Axsome Therapeutics Inc ,Drug Administration ,Development Pipeline ,National Post ,Blackberry Ltd ,Therapeutics Reports Fourth Quarter ,Full Year ,Provides Business ,Joeo Connor ,Victoria Wells ,Financial Times ,Financial Post ,New York Times ,Axsome Therapeutics ,Chief Executive Officer ,Full Year Financial ,Postmedia Network ,Top Stories ,Digital Centric Commercialization ,Breakthrough Therapy ,Disease Agitation ,New Drug Application ,Deficit Hyperactivity Disorder ,Depressive Disorder ,Eating Disorder ,Work Disorder ,Trial Topline Results ,Trial Initiations ,Industry Minister Fran ,Philippe Champagne ,